Intractable disease drug "Zolgensuma" Adjusted at about 167 million yen per time 20:51 May 11
Regarding the "Zolgensma," which is said to be the "highest in the world," for the treatment of intractable diseases such as young children, the Ministry of Health, Labor and Welfare will apply insurance to make adjustments in the direction of approximately 167 million yen per time. We are.
"Zolgensma" is a therapeutic drug for spinal muscular atrophy, an intractable disease that causes muscle weakness throughout the body, such as in young children, and was approved by the government in March this year.
It is said to be the most expensive drug in the world, exceeding 200 million yen per dose in the United States, so domestic pricing is drawing attention.
Under these circumstances, the Ministry of Health, Labor and Welfare made it clear that “Zolgensma” is subject to the application of public medical insurance, and the adjustments are being made in the direction of approximately 167 million yen per time. If approved by the Chuikyo-Central Social Insurance Medical Council held on the 13th, it will be the most expensive drug currently covered by insurance in Japan.
It is estimated that about 25 patients will be covered annually, and there will be an upper limit to the medical expenses paid by the patient, and any excess will be covered by insurance premiums.